2. Search Result
Search Result
Results for "

Shc

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Antibodies

8

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125857C
    Cytochrome C (bovine heart)

    		Biochemical Assay Reagents Apoptosis Reactive Oxygen Species (ROS) Caspase Metabolic Disease
    Cytochrome C (bovine heart) is composed of 104 amino acids and is a nuclear-encoded mitochondrial protein. Cytochrome C (bovine heart) acts as an effective ROS scavenger, but when combined with the cofactor p66Shc, it promotes the generation of ROS to initiate apoptosis. Cytochrome C (bovine heart) can act as a single electron carrier .
    Cytochrome C (bovine heart)
  • HY-14604
    Xaliproden hydrochloride
    1 Publications Verification

    SR57746A; SR57746 hydrochloride

    		 5-HT Receptor Dopamine Receptor Trk Receptor PKC ERK Akt JNK Neurological Disease Metabolic Disease
    Xaliproden (SR57746) hydrochloride (SR57746A) is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden hydrochloride activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden hydrochloride also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ 35S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden hydrochloride exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden hydrochloride also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden hydrochloride can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .
    Xaliproden hydrochloride
  • HY-161464
    Chlopynostat

    		HDAC Apoptosis Cancer
    Chlopynostat (Compound 6c) is a HDAC1 inhibitor with a IC50 value of 67 nM. Chlopynostat reverses STAT4/p66Shc defects by inhibiting HDAC1-induced < b>Apoptosis .
    Chlopynostat
  • HY-168867
    RD-23

    		PROTACs RET Apoptosis Cancer
    RD-23 is an orally active and selective RET PROTAC degrader, with DC50 values of 5.6 nM and 11.7 nM against RET WT and RET G810C mutants, respectively. RD-23 inhibits purified RET kinase activity with an IC50 of 0.371 nM. RD-23 suppresses the activation of downstream Shc signaling and induces apoptosis. RD-23 can be used for the research of RET-related cancers .
    RD-23
  • HY-RS12858
    SHC3 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SHC3 Human Pre-designed siRNA Set A contains three designed siRNAs for SHC3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SHC3 Human Pre-designed siRNA Set A
    SHC3 Human Pre-designed siRNA Set A
  • HY-178061
    APS03118

    		ERK RET Cancer
    APS03118 is an orally active, potent and selective rearranged during transfection (RET) inhibitor. APS03118 broadly inhibits RET fusions and mutations (including G810, V804, L730, and Y806 variants), with IC50 values predominantly below 1 nM (0.095 nM for WT; ranging from 0.00438 to 5.72 nM for mutants), and demonstrates marked superiority against RET G810 mutations. APS03118 inhibits the entire RET signaling pathway (including RET, Shc, and ERK1/2), with >20-fold selectivity over most off-target kinases (except FLT3 and YES). APS03118 induces complete tumor regression in KIF5B-RET and CCDC6-RET V804 M patient derived xenografts (PDXs) and significantly prolongs survival in an intracranial CCDC6-RET metastasis mice model. APS03118 can be used for selective RET inhibitor (SRI)-resistant, RET-driven cancer research .
    APS03118
  • HY-RS12856
    SHC1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SHC1 Human Pre-designed siRNA Set A contains three designed siRNAs for SHC1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SHC1 Human Pre-designed siRNA Set A
    SHC1 Human Pre-designed siRNA Set A
  • HY-RS21432
    Shc1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Shc1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Shc1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Shc1 Mouse Pre-designed siRNA Set A
    Shc1 Mouse Pre-designed siRNA Set A
  • HY-RS12859
    SHC4 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SHC4 Human Pre-designed siRNA Set A contains three designed siRNAs for SHC4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SHC4 Human Pre-designed siRNA Set A
    SHC4 Human Pre-designed siRNA Set A
  • HY-RS12857
    SHC2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    SHC2 Human Pre-designed siRNA Set A contains three designed siRNAs for SHC2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SHC2 Human Pre-designed siRNA Set A
    SHC2 Human Pre-designed siRNA Set A
  • HY-151987
    RET-IN-20

    		RET Apoptosis Cancer
    RET-IN-20 is a potent RET inhibitor with an IC50 value of 13.7 nM. RET-IN-20 decreases the expression of p-Ret, p-Shc protein. RET-IN-20 induces apoptosis. RET-IN-20 shows antiproliferative and anti-tumor activity .
    RET-IN-20
  • HY-170926
    CQ1373

    		RET Apoptosis Cancer
    CQ1373 is a potent RET inhibitor, demonstrating cellular potency with IC50 values of 13.0, 25.7 and 28.4 nM against BaF3 cells expressing CCDC6-RET, CCDC6-RET-G810C and CCDC6-RET-G810R, respectively. CQ1373 exhibits good selectivity toward wild-type RET and solvent front mutants G810C/R with IC50 values of 4.2, 7.1 and 32.4 nM, respectively. CQ1373 inhibits RET phosphorylation and downstream signaling through SHC. CQ1373 induces Apoptosis and cell cycle arrest in BaF3 cells. CQ1373 exhibits anti-tumor efficacy and can be used for cancer research .
    CQ1373
  • HY-119820
    Xaliproden free base

    SR57746A free base

    		 Akt Dopamine Receptor Trk Receptor 5-HT Receptor PKC JNK ERK Neurological Disease
    Xaliproden (SR57746) free base is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden free base activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden free base also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ 35S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden free base exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden free base also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden free base can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .
    Xaliproden free base
  • HY-RS27950
    Shc1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Shc1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Shc1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Shc1 Rat Pre-designed siRNA Set A
    Shc1 Rat Pre-designed siRNA Set A
  • HY-RS22323
    Shc3 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Shc3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Shc3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Shc3 Mouse Pre-designed siRNA Set A
    Shc3 Mouse Pre-designed siRNA Set A
  • HY-RS28845
    Shc3 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Shc3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Shc3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Shc3 Rat Pre-designed siRNA Set A
    Shc3 Rat Pre-designed siRNA Set A
  • HY-183684
    RET-IN-33

    		RET VEGFR PDGFR Akt ERK Endocrinology Cancer
    RET-IN-33 is a moderately selective inhibitor of RET mutants. RET-IN-33 potently inhibits G810 mutants, with IC50 values of 4.43 nM (G810R), 3.28 nM (G810C) and 0.51 nM (G810S), respectively. RET-IN-33 also inhibits other RET mutants: V804M (IC50 0.73 nM), V804L (IC50 0.36 nM), Y806H (IC50 0.74 nM) and M918T (IC50 0.55 nM). RET-IN-33 also inhibits other kinases, with an IC50 of 1.50 nM against VEGFR2 and 1.60 nM against PDGFRα. RET-IN-33 blocks the autophosphorylation of RET mutants and the downstream SHC/AKT/ERK signaling pathway. RET-IN-33 selectively inhibits the proliferation of RET-driven cell models without affecting non-RET-dependent or normal cells. RET-IN-33 exhibits dose-dependent antitumor efficacy in RET-driven xenograft models. RET-IN-33 can be used for the research of medullary thyroid carcinoma, papillary thyroid carcinoma and non-small cell lung cancer .
    RET-IN-33
  • HY-14604R
    Xaliproden hydrochloride (Standard)

    SR57746A (Standard); SR57746 hydrochloride (Standard)

    		 Reference Standards Akt Dopamine Receptor Trk Receptor 5-HT Receptor PKC JNK ERK Neurological Disease Cancer
    Xaliproden (hydrochloride) (Standard) is the analytical standard of Xaliproden (hydrochloride). This product is intended for research and analytical applications. Xaliproden (SR57746) hydrochloride (SR57746A) is an orally active, highly selective 5-HT1A receptor agonist. Xaliproden hydrochloride activates pertussis toxin-sensitive G protein-coupled signaling cascades, as well as the PKC, ERK1/ERK2, Akt and p21 Ras/MEK-1 pathways. Xaliproden hydrochloride also downregulates the JNK/p66/c-Jun signaling pathway, induces phosphorylation of the shc adaptor protein, regulates extracellular dopamine and 5-HT levels, and induces [ 35S]GTPγS labeling in rat brain structures rich in 5-HT1A receptors. Xaliproden hydrochloride exerts neurotrophic, neuroprotective, renoprotective, anti-inflammatory, anti-apoptotic, anti-fibrotic and analgesic effects. Xaliproden hydrochloride also enhances NGF-induced neurite outgrowth, promotes motor neuron survival, attenuates renal tubular injury and inhibits chemotherapy-induced mechanical allodynia, without activating or altering NGF-induced TrkA receptor activation. Xaliproden hydrochloride can be used in the research of motor neuron disease, diabetic nephropathy, chemotherapy-induced peripheral neuropathy, amyotrophic lateral sclerosis, Alzheimer's disease, acute tonic nociceptive pain, inflammatory pain, depression and anxiety .
    Xaliproden hydrochloride (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: